🔎 Trials Near Me

Utama › Neuroblastoma › Pennsylvania

Kajian klinikal Neuroblastoma di Pennsylvania

14 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di Pennsylvania.

Bandar di Pennsylvania

Teks kajian rasmi (Bahasa Inggeris)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Children's Hospital of Philadelphia, Philadelphia
  • dan 2 lagi
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Mengambil pesertaFasa 2
Sehingga umur 22 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Mengambil pesertaFasa 1/2
Sehingga umur 26 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Mengambil pesertaFasa 1/2
Sehingga umur 30 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06541262

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Mengambil pesertaFasa 2
Umur 1 hingga 21 · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06540963

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • dan 2 lagi
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital of Philadelphia, Philadelphia
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Mengambil pesertaFasa 2
12 Months – 21 Years · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT05489887

SPEARHEAD-3 Pediatric Study

  • Children's Hospital of Philedephia, Philadelphia
Mengambil pesertaFasa 1/2
Umur 2 hingga 21 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05642455

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaFasa 1/2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06721689

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  • Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaFasa 2
Umur 1 hingga 31 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT06450041

Neuroblastoma Biology Study

  • Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaKajian pemerhatian
31 Days – 99 Years · Semua jantina · Dikemas kini 23 Mac 2026 · NCT01587300

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  • Children's Hospital of Philadelphia, Philadelphia
Mengambil peserta
Sehingga umur 17 · Semua jantina · Dikemas kini 10 Feb 2026 · NCT06831552

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.